VectivBio Holding AG (VECT)

NASDAQ: VECT · IEX Real-Time Price · USD
4.90
-0.10 (-2.00%)
At close: Jan 14, 2022 4:00 PM
4.95
0.05 (1.02%)
After-hours:Jan 14, 2022 4:25 PM EST
Market Cap175.72M
Revenue (ttm)n/a
Net Income (ttm)-59.94M
Shares Out35.86M
EPS (ttm)-5.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,648
Open4.81
Previous Close5.00
Day's Range4.81 - 5.04
52-Week Range2.74 - 37.70
Betan/a
AnalystsStrong Buy
Price Target25.50 (+420.4%)
Earnings Daten/a

About VECT

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

IndustryBiotechnology
IPO DateApr 9, 2021
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolVECT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for VECT stock is "Strong Buy." The 12-month stock price forecast is 25.50, which is an increase of 420.41% from the latest price.

Price Target
$25.50
(420.41% upside)
Analyst Consensus: Strong Buy

News

VectivBio Announces Third Quarter 2021 Business Update

-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022-

2 months ago - GlobeNewsWire

VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference

BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for sever...

2 months ago - GlobeNewsWire

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

-FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease

2 months ago - GlobeNewsWire

VectivBio Announces Closing of Comet Therapeutics Acquisition

- Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases - - Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases -

3 months ago - GlobeNewsWire

VectivBio Announces Upcoming Investor Events

Company to host an R&D Day on September 21, 2021 Company to host an R&D Day on September 21, 2021

4 months ago - GlobeNewsWire

VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary

Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities

4 months ago - GlobeNewsWire

VectivBio Announces Results of Extraordinary General Meeting

Paul R. Carter and Murray W. Stewart Elected to the Board of Directors Paul R. Carter and Murray W. Stewart Elected to the Board of Directors

4 months ago - GlobeNewsWire

VectivBio to Acquire Comet Therapeutics and Host R&D Day

- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline - - VectivBio to Host R&D Day on September 21, 2021-

4 months ago - GlobeNewsWire

VectivBio Publishes Invitation to the Extraordinary General Meeting

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...

5 months ago - GlobeNewsWire

VectivBio Nominates Paul R. Carter and Murray W.

- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on Sep...

6 months ago - GlobeNewsWire

VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease

Phase 2 trial expected to begin in the first quarter of 2022 Phase 2 trial expected to begin in the first quarter of 2022

6 months ago - GlobeNewsWire

VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients wit...

Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IF CIC patients represent over half of the total SBS-IF population...

7 months ago - GlobeNewsWire

VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer

Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of a...

7 months ago - GlobeNewsWire

CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence of t...

9 months ago - GlobeNewsWire

VectivBio Announces Closing of $146.6 Million Initial Public Offering

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development an...

9 months ago - GlobeNewsWire

Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today

Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM...

Other symbols:RPHM
9 months ago - InvestorPlace

VectivBio Announces Pricing of Initial Public Offering

BASEL, Switzerland, April 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development an...

9 months ago - GlobeNewsWire